ONK Therapeutics is a technology company.
ONK Therapeutics has raised $22.0M across 1 funding round.
ONK Therapeutics has raised $22.0M in total across 1 funding round.
ONK Therapeutics is a biotechnology company developing next-generation, off-the-shelf natural killer (NK) cell therapies for hematological malignancies like multiple myeloma and acute myeloid leukemia, as well as solid tumors.[1][2][3][6] Its proprietary platform engineers NK cells with genetic modifications, including chimeric antigen receptors (CARs) targeting tumor antigens and TRAIL variants for death receptor pathways (DR4/DR5), to enhance cytotoxicity, persistence, metabolic health, and resistance to exhaustion in the tumor microenvironment.[1][2][3] The lead candidate, ONKT102, is an optimized CD38 CAR-NK therapy for relapsed/refractory multiple myeloma, with a preclinical pipeline including ONKT104 (AML), ONKT105/ONKT103 (solid tumors), and ONKT106.[2][4][6] Founded in 2015 and backed by $21.5 million in Series A financing in 2022, ONK operates transatlantically from Ireland and the US, advancing toward clinical trials while securing patents and partnerships like those with Intellia Therapeutics and NAYA Biosciences.[2][3][4]
ONK Therapeutics was founded in 2015 in Galway, Ireland, based on NK cell and apoptosis research by its founder, Prof. M. O’Dwyer, MD, and collaborators at the University of Galway.[1] The idea emerged from harnessing the innate biology of NK cells—immune cells that naturally target cancer—through proprietary engineering to overcome limitations like poor persistence and tumor escape.[1][3][7] Early traction came from platform development, including licensing CRISPR/Cas9 from Intellia Therapeutics and global CISH knockout technology from WEHI, enabling optimized edits like inhibitory receptor deletions (e.g., CD96, Siglec-7).[2][3] By 2022, a $21.5 million Series A round fueled US expansion to San Diego and preclinical progress, earning recognition as BioSpace's Most Promising Company in 2023.[2][4][7] Key hires like Chief Scientific Officer Bruce McCreedy, PhD, bolstered drug development expertise.[5]
ONK stands out in the NK cell therapy field through its proprietary, dual-targeted platform that combines CARs with TRAIL variants, reducing antigen escape risks and broadening applicability across tumor types.[1][2][3]
ONK Therapeutics rides the explosive growth in NK cell therapies, a hot segment in cell therapy projected to surpass CAR-T limitations like manufacturing complexity and toxicity, amid a shift toward off-the-shelf solutions.[2][3][7] Timing aligns with advances in gene editing (CRISPR) and apoptosis pathways, enabling dual-targeting to combat resistance—critical as solid tumors resist CAR-T.[1][2] Market forces favor ONK: rising cancer incidence, demand for myeloma/AML treatments post-relapse, and investor interest in scalable NK platforms (evidenced by its Series A and BioSpace nod).[2][4] It influences the ecosystem by pioneering NK optimizations, patenting key tech like CISH KO, and partnering academically/industrially to accelerate clinical translation from Ireland to US hubs.[3][7]
ONK is poised to enter clinical trials with ONKT102 in 2026, leveraging its platform's preclinical momentum and recent partnerships to test in myeloma combos.[2][3][6] Trends like AI-driven editing, bispecific synergies, and iPSC-derived NKs will shape its path, potentially expanding to more solid tumor indications.[3][6][7] Influence may grow via IND filings, further funding, and leadership in "next-gen" NK, ultimately challenging T-cell dominance if dual-targeting proves superior against escape. This positions ONK as a transatlantic biotech frontrunner, transforming off-the-shelf NK from promise to cure.[1][2]
ONK Therapeutics has raised $22.0M in total across 1 funding round.
ONK Therapeutics's investors include Acorn Bioventures.
ONK Therapeutics has raised $22.0M across 1 funding round. Most recently, it raised $22.0M Series A in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2022 | $22.0M Series A | Acorn Bioventures |